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Circulating branched-chain amino acid (BCAA) levels
are elevated in obesity/diabetes and are a sensitive
predictor for type 2 diabetes. Here we show in rats
that insulin dose-dependently lowers plasma BCAA
levels through induction of hepatic protein expres-
sion and activity of branched-chain a-keto acid de-
hydrogenase (BCKDH), the rate-limiting enzyme in
the BCAA degradation pathway. Selective induction
of hypothalamic insulin signaling in rats and genetic
modulation of brain insulin receptors in mice demon-
strate that brain insulin signaling is a major regulator
of BCAA metabolism by inducing hepatic BCKDH.
Short-term overfeeding impairs the ability of brain
insulin to lower BCAAs in rats. High-fat feeding in
nonhuman primates and obesity and/or diabetes
in humans is associated with reduced BCKDH pro-
tein in liver. These findings support the concept
that decreased hepatic BCKDH is a major cause of
increased plasma BCAAs and that hypothalamic in-
sulin resistance may account for impaired BCAA
metabolism in obesity and diabetes.
INTRODUCTION
The branched-chain amino acids (BCAAs), e.g., leucine, isoleu-
cine, and valine, are essential amino acids that are elevated in
obesity and type 2 diabetes, and they have recently emerged
as a predictor for the future risk of diabetes (Wang et al., 2011).
In obese and/or diabetic humans and rodents, BCAA levels and
their incompletely oxidized degradation products, the short-898 Cell Metabolism 20, 898–909, November 4, 2014 ª2014 Elsevierchain acylcarnitines, are elevated in plasma and/or tissues (Kim
et al., 2010; Laferre`re et al., 2011; Lanza et al., 2010; Mihalik
et al., 2010; Newgard et al., 2009; She et al., 2007), suggesting
that alterations in catabolism of BCAAs may play an important
role in both insulin resistance and diabetes. Improvements in in-
sulin sensitivity in response to a dietary/behavioral weight loss
intervention and to bariatric surgery are associated with lower
circulating BCAA levels (Laferre`re et al., 2011).
The mechanisms that are responsible for the elevation in
plasmaBCAAs inobeseand/or diabetic individuals remainpoorly
understood and may be attributed to increased protein intake.
However, even when protein intake was matched, diabetics
had higher circulating BCAA levels compared to lean nondiabetic
individuals (Tai et al., 2010). Increased proteolysis and/or
reduced protein synthesis may account for decreased BCAA uti-
lization leading to elevated circulating BCAA levels, but whole-
body protein degradation and/or synthesis does not seem to
differ between normal and diabetic individuals (Barazzoni et al.,
2003; Halvatsiotis et al., 2002; Luzi et al., 1993; Tessari et al.,
2005). Hence, reduced catabolism of BCAAs could be a major
cause for the elevatedBCAA levels seen in obese and/or diabetic
individuals, which is supported by the finding that BCAA-catabo-
lizing enzymes are decreased in fat and liver in genetically obese
ob/ob mice and fa/fa rats (She et al., 2007).
BCAA catabolism starts with transamination of circulating
BCAAs to a-keto acids by branched-chain aminotransferase
(BCATm), expressed mainly in muscle, kidney, and heart (Harper
et al., 1984; Hutson et al., 2005). The keto acid products are then
released back into the circulation, and upon entering the liver,
they are oxidatively decarboxylated to acyl coenzyme A (acyl-
CoA) derivatives by the rate-limiting enzyme, branched-chain
a-ketoacid dehydrogenase (BCKDH). While both adipose tissue
and the liver perform oxidative decarboxylation of keto acids, the
liver is believed to be the organ with higher protein expression
and activity of BCKDH (Suryawan et al., 1998), although as of yetInc.
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tissues.
While the nutritional and hormonal regulation of BCAA meta-
bolism through a variety of hormones such as thyroid hormones
and glucocorticoids has been studied (Shimomura et al., 2001),
surprisingly, the role of glucose and insulin in regulating BCAA
catabolism is incompletely understood. Here we probe the role
of insulin signaling in regulating BCAA catabolism and demon-
strate that neuronal insulin signaling is an important pathway
that controls hepatic BCAA catabolism, which is evolutionarily
conserved from C. elegans to mammals.
RESULTS
Insulin Lowers Plasma BCAA Levels and Induces
Hepatic BCKDH Expression and Activity
Obesity and prediabetes are characterized by insulin resistance
and transient elevations in circulating glucose levels, both of
which may affect BCAA metabolism (Palmer et al., 1985).
Thus, we first set out to disentangle the role of insulin versus
glucose in regulating BCAA metabolism in vivo. To delineate
the physiological role of insulin in the regulation of circulating
BCAA levels, we performed euglycemic clamps with plasma in-
sulin at basal (1 mU/kg/min) or induced moderate (3 mU/kg/min)
or marked hyperinsulinemic (8 or 16 mU/kg/min) levels in 10-
week-old male Sprague-Dawley (SD) rats (experimental protocol
depicted in Figure 1A). This protocol allowed us to probe the role
of insulin in regulating BCAAs independent of perturbations in
glycemia. Somatostatin was infused during 1 and 3 mU clamps
to prevent endogenous insulin secretion and control counterre-
gulatory hormones such as glucagon. Plasma insulin levels
increased dose-dependently, as did the glucose infusion rate
(GIR) that was required to maintain euglycemia. Likewise, key
parameters of insulin action, such as the rate of glucose disposal
(Rd) and the percent suppression of hepatic glucose production
(hGP), increased with higher circulating insulin levels (Figure S1,
available online). Total plasma BCAA levels were equally
matched between all groups prior to the clamps as assessed
through a spectrophotometric assay that measures NADH
generated from BCAA oxidation by leucine dehydrogenase
(Beckett, 2000). Insulin rapidly and dose-dependently lowered
plasma BCAA levels (Figure 1B), indicating that insulin is a major
regulator of circulating BCAA levels. Since food had been
removed at the start of the experiment, the animals transitioned
into a fasting state during the clamp, and therefore, the lowering
of plasma BCAA levels cannot be explained by reduced BCAA
absorption in the gut, but instead could be due to alterations in
BCAA metabolism.
The first step in BCAA catabolism is the conversion of BCAAs
into branched-chain a-keto acids, which is catalyzed by the
enzyme BCATm in most peripheral tissues except the liver. The
second and rate-limiting step is the oxidative decarboxylation
of branched-chain a-keto acids into acyl-CoAs catalyzed by
BCKDH. BCKDH is expressed in both adipose tissue and liver,
and its activity is inhibited by phosphorylation. We therefore
measured protein expression of BCATm in muscle, and in liver
and adipose tissue we measured both protein levels and activa-
tion state of BCKDH, the latter through a phospho-specific anti-
body. BCATm levels were not altered by insulin in any of theCell Mgroups. However, in the livers of the 16 mU/kg/min clamped an-
imals the expression of BCKDH protein was increased, while
levels of phospho-BCKDH were reduced (Figures 1C and 1D).
Since phosphorylation of BCKDH inactivates the enzyme, these
data indicate that insulin enhances BCKDH activity both by
increasing its expression and by decreasing its phosphorylation.
To confirm that insulin indeed increases BCKDH activity, we
determined the rate of oxidation of ketoisovalerate (KIV) in hepat-
ic extracts.Hyperinsulinemia increasedBCKDHactivity, confirm-
ing that the insulin-induced expression and dephosphorylation of
BCKDH protein resulted in an increase in activity (Figure 1E).
BCKDH is also expressed in white adipose tissue (WAT),
where BCKDH protein levels were higher in the 3 mU/kg/min
group but lower in the 16 mU/kg/min group compared to con-
trols (Figure S1), indicating that BCKDH in WAT is less or less
consistently regulated by insulin compared to hepatic BCKDH.
However, BCKDH protein levels may not adequately reflect its
activity. To estimate the relative BCKDH activity in adipose tis-
sue versus liver, we determined the enzymatic activity of BCKDH
in WAT. BCKDH activity in perigonadal WAT was significantly
lower compared to its activity in liver (Figures 1 and S1). These
data support the notion that insulin primarily regulates BCKDH
activity in liver and that WAT BCKDH plays only a minor role in
systemic BCAA metabolism in lean SD rats.
Hyperglycemia per se Does Not Increase Circulating
BCAAs
In vitro evidence indicates that BCAA catabolism is inhibited by
glucose, but to our knowledge there have been no in vivo studies
which have investigated the role of glucose on BCAA catabolism
independent of insulin (Palmer et al., 1985). We therefore studied
the effects of increases in glycemia on BCAA levels and hepatic
BCKDH expression. To this end, we performed hyperglycemic
clamps during which we raised glucose levels to 330–360 mg/dl
for 2 hr by infusing a variable rate of 45% glucose intravenously
while maintaining basal insulin levels (Figure S2). Transient hy-
perglycemia per se did not alter plasma BCAA levels (Figure 1F),
indicating that evenmarked changes in circulating glucose levels
have little effect on BCAAmetabolism in the absence of concom-
itant elevations of insulin. Taken together, these data demon-
strate that insulin lowers circulating BCAA levels through induc-
tion of hepatic BCKDH protein expression and activity,
independent of changes in glycemia.
Brain Insulin Signaling Controls Circulating BCAA
Levels by Inducing Hepatic BCKDH Expression and
Activity
Insulin regulates glucose and lipid metabolism in target tissues,
such as the liver and adipose tissue, both through direct effects
mediated via the insulin receptors expressed in these tissues
and indirectly by orchestrating organ crosstalk where brain insu-
lin signaling plays a critical role. For example, insulin suppresses
hepatic glucose production and lipolysis in adipose tissue via
cell-autonomous effects and through signaling in themediobasal
hypothalamus (MBH) that alters parasympathetic and sympa-
thetic outflow to these tissues, respectively (Pocai et al., 2005;
Scherer et al., 2011). To initially test if BCAA metabolism is regu-
lated through neuroendocrine mechanisms, we infused 2-deox-
yglucose (2-DG) intracerebroventricularly (i.c.v.) to induceetabolism 20, 898–909, November 4, 2014 ª2014 Elsevier Inc. 899
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Figure 1. Insulin, but Not Glucose, Regulates Circulating BCAAs and Hepatic BCAA Metabolism
(A) Schematic representation of basal or hyperinsulinemic euglycemic clamp protocols in SD male rats.
(B) Plasma BCAA levels at the end of the clamp as measured by spectrophotometric assay (nR 5 per group).
(C) Hepatic protein expressions of BCKDH and its phosphorylation state by western blot (nR 6 per group).
(D) The ratio of inactive BCKDH to total BCKDH protein in liver as an index of BCKDH activity (nR 6 per group).
(E) Hepatic BCKDH activity as measured by a-ketoisovalerate (KIV) oxidation assay using 1-14C isotope (nR 4 per group).
(F) Circulating BCAAs at the end of hyperglycemic clamps (nR 5 per group). *p < 0.05 compared to basal condition. Values are mean ± SEM.
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Brain Insulin Controls BCAA Metabolismglucopenia in the CNS, thereby triggering the counterregulatory
response. Plasma BCAA levels trended to be higher 60 and
90 min after the i.c.v. 2-DG injection (Figure S2). Since central
2-DG injection activates both the autonomic nervous system
and the secretion of counterregulatory hormones such as
glucagon and corticosterone, these data suggest that BCAA
metabolism is regulated by either counterregulatory hormones
or the autonomic nervous system.
Hypothalamic insulin controls hepatic and adipose tissue
metabolism via the autonomic nervous system (Buettner andCa-
macho, 2008; Scherer et al., 2011). To examine a potential role of
hypothalamic insulin signaling in regulating BCAA metabolism
that occurs independent of counterregulatory hormones, we900 Cell Metabolism 20, 898–909, November 4, 2014 ª2014 Elsevierinfused insulin (2 mU) or vehicle (artificial cerebrospinal fluid;
aCSF) into the MBH of SD rats over 6 hr (as described above).
Since insulin infusion into the CNS can alter circulating insulin
and glucose levels (Scherer et al., 2011), we infused insulin at
1 mU/kg/min to maintain systemic insulin at basal levels and
clamped glucose at euglycemic levels (Figure 2A). Animals
infusedwithMBH insulin required a higher GIR tomaintain eugly-
cemia. This increase in GIR was due to a greater suppression of
hGP (Figure S3), while peripheral glucose utilization as assessed
by the Rd was unchanged, consistent with prior studies (Scherer
et al., 2011). Plasma insulin levels during the clamps were not
different between groups (Figure S3). Since the animal transi-
tioned to a fasting state during the clamp, BCAA levels graduallyInc.
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Brain Insulin Controls BCAA Metabolismincreased in MBH vehicle-infused animals. Importantly, MBH in-
sulin was able to prevent this rise and even lowered plasma
BCAAs (Figures 2B, 2C, and S3), demonstrating that hypotha-
lamic insulin controls circulating BCAA levels. Since systemic
hyperinsulinemia induced BCKDH expression in the liver, we
next asked whether MBH insulin is sufficient to regulate hepatic
BCKDH expression. Indeed, MBH insulin infusion induced he-
patic BCKDH protein expression and activity (Figures 2E–2G).
Further, we observed a significant increase of BCKDH protein
expression in white adipose tissue in the MBH infusion group
compared to the controls (Figure S3).
Notably, systemically administered leptin can also reduce
circulating BCAAs comparable to systemically administered
insulin in a mouse model of type 1 diabetes (Wang et al.,
2010). Both of these hormones regulate systemic metabolism
in part through signaling in the MBH (Buettner et al., 2008;
Scherer et al., 2011). Thus, we next tested whether central
leptin signaling regulates circulating BCAA levels. Indeed,
MBH-infused leptin also lowered BCAAs similar to MBH insulin
(Figure S3), suggesting that leptin and insulin exert similar
effects on the regulation of BCAA metabolism via signaling in
the CNS.
Brain Insulin Signaling Induces Several BCAA Catabolic
Enzymes in Addition to BCKDH and Decreases
Incomplete Degradation Products of BCAAs
Apart from BCKDH, the second enzyme in the BCAA degrada-
tion pathway, several other enzymes downstream of BCKDH
further catabolize BCAA to acetyl-CoA. Since antibodies to
these proteins are not commercially available, we performed
a global quantitative proteomic profiling by 2D liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS) coupled
with iTRAQ (isobaric tag for relative and absolute quantitation)
labeling (Sigdel et al., 2014) to investigate whether MBH insulin
induced downstream BCAA-catabolizing enzymes. This proteo-
mic analysis led to the identification and quantification of 2,418
proteins in these liver extracts, of which 250 were significantly
altered by MBH insulin infusion. Interestingly, five of these pro-
teins, i.e., acyl-CoA dehydrogenase, aldehyde dehydrogenase,
3-Methylcrotonyl-CoA carboxylase, enoyl-CoA hydratase, and
dihydrolipoyl dehydrogenase (E3 component of BCKDH com-
plex), are enzymes involved in BCAA degradation, and all of
these proteins were significantly induced in livers of rats infused
with MBH insulin (Figure 2H). Incomplete degradation of BCAAs
can lead to accumulation of partially oxidized intermediates in
tissues and circulation, which has been described in obesity
and insulin-resistant states, giving rise to the notion that
BCAA catabolism is reduced in these conditions (Laferre`re
et al., 2011; Newgard et al., 2009). If indeed BCAA degradation
is enhanced by MBH insulin as suggested by the upregulation
of several catabolic enzymes and the reduction in circulating
BCAAs, incompletely oxidized BCAA intermediates should
also be reduced. To measure plasma short-chain acylcarni-
tines—C3, C4-DC, C5s, and C5-OH—and liver acyl-CoAs
such as 3-methylcrotonyl CoA and propionyl CoA, we utilized
targeted metabolomics. This analysis revealed that incomplete
degradation products such as propionyl-CoA and 3-methylcro-
tonyl-CoA were lowered by MBH insulin (Figures 2I and 2J),
whereas the end product acetyl-CoA was increased in liverCell M(Figure 2I), indicating that brain insulin facilitates BCAA
catabolism.
Some non-BCAA amino acids, such as phenylalanine and
asparagine, were also reduced after insulin infusion in the MBH
(Figure S3). However, our proteomics analysis did not reveal
changes in any of their catabolic enzymes, such as phenylala-
nine hydroxylase, transaminase, or L-asparaginase, indicating
that the hepatic expression of BCAA-catabolizing enzymes is
uniquely under the control of MBH insulin.
BCAA Homeostasis Is Impaired in a Mouse Model
of Neuronal Insulin Receptor Deficiency
To test whether lifelong brain insulin resistance alters BCAA
metabolism, we studied BCAA homeostasis in neuronal insulin
receptor knockout mice (NIRKO) during the fast-to-fed transition
as previously described (Scherer et al., 2011) (protocol depicted
in Figure 3A). Notably, NIRKOmice exhibit impaired regulation of
lipid and glucose partitioning when studied with tracer dilution
technique, although their fasting plasma lipid and glucose levels
remain normal compared to wild-types when fed a standard
chow diet (Diggs-Andrews et al., 2010; Scherer et al., 2011). In
the fasting state, BCAA levels were not different between both
strains. However, after refeeding, plasma BCAA levels were
suppressed in the wild-types, likely due to higher insulin levels
in the postprandial state, and this suppression of plasma BCAAs
was significantly diminished (50%) in NIRKO mice (Figure 3B),
consistent with impaired BCAA homeostasis in the absence of
brain insulin receptors.
Inducible Deletion of the IR in Peripheral Tissues,
Including the Liver, Does Not Increase Circulating BCAA
Levels, but Inducible Whole-Body IR Deficiency Does
Lifelongknockoutmodels suchas theNIRKOmicehave twomain
drawbacks in the study of physiology. First, a protein such as the
insulin receptor (IR) may have an important role during develop-
ment thatmay differ from its physiological role in adulthood. Sec-
ond, because of developmental plasticity,metabolic defectsmay
be ‘‘rescued’’ through the activation of compensatory pathways.
These issues can largely be avoided through the use of inducible
knockout mouse models, as these animals undergo normal
development, and the insulin receptor is deleted only after devel-
opment is complete. Therefore, we studied BCAA metabolism in
two inducible knockout mouse models: first where the insulin re-
ceptor is knockedout in all peripheral tissues, suchasadipose tis-
sue, liver, and muscle, but not the CNS (IRDPER), and second
where the insulin receptor is knocked out in the whole body,
including the CNS (IRDWB) (Koch et al., 2008). Body weight was
comparable between NIRKOs (mean ± SEM; 23.2 ± 0.6 g) and
IRDPER mice (23.2 ± 1.1 g) and slightly higher in the IRDWB mice
(25.8 ± 0.7 g). Both IRDPER and IRDWB mice developed compara-
ble hyperglycemia and marked hyperinsulinemia (Figure S2), the
latter due to the absence of the hepatic insulin receptor that is
required for insulin clearance. Since insulin receptor signaling in
the brain is intact in the IRDPER mice, we hypothesized that brain
insulin signaling would be enhanced due to the marked hyperin-
sulinemia, resulting in increased hepatic BCAA catabolism, and
thus lower circulating BCAA levels. On the other hand, in the
IRDWB mice whose brain insulin receptor expression is markedly
reduced, insulin should be unable to regulate BCAA metabolismetabolism 20, 898–909, November 4, 2014 ª2014 Elsevier Inc. 901
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Figure 2. Acute MBH Insulin Infusion Lowers Circulating BCAAs and Induces Hepatic BCKDH Protein
(A) Schematic representation of euglycemic clamp protocol paired with MBH insulin infusion.
(B) Total plasma BCAA levels at baseline and at the start and the end of the clamps (nR 4 per group).
(C) Individual plasma BCAA levels (nR 4 per group).
(D) Schematic depiction of the simplified BCAA catabolic pathway, with enzymes whose protein levels are regulated by MBH insulin highlighted in red color.
(legend continued on next page)
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Figure 3. Lack of CNS Insulin Signaling Leads to Impaired Regulation of BCAA Metabolism
(A) Schematic representation of fasting and refeeding protocol in NIRKO mice.
(B) Plasma BCAA levels at fasting and refed states in NIRKO mice (nR 5 per group).
(C) Plasma BCAA levels in IRDWB mice after overnight fasting (n = 8 per group).
(D) Plasma BCAA levels in IRDPER mice after overnight fasting (nR 7 per group).
(E) Hepatic protein expressions of BCKDH and phosphorylated, inactive form of BCKDH by western blot in IRDWBmice after overnight fasting (nR 4 per group).
(F) Hepatic protein expressions of BCKDH and phosphorylated, inactive form of BCKDH by western blot in IRDPERmice after overnight fasting (nR 4 per group).
*p < 0.05 compared to control group. Values are mean ± SEM.
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IRDWBmice hadhigher plasmaBCAA levels compared to the con-
trols after an overnight fast, while IRDPER mice had lower plasma
BCAA levels compared to control animals (Figures 3C and 3D).
Correspondingly, hepatic BCKDH protein expression was lower
in IRDWB and higher in IRDPER mice after fasting (Figures 3E and
3F). Taken together, these data confirm in genetic models that(E) Hepatic protein expressions of total and phosphorylated BCKDH by western
(F) The ratio of inactive BCKDH to total BCKDH protein in liver as an index of BC
(G) Hepatic BCKDH activity as measured by a-ketoisovalerate (KIV) oxidation us
(H) Relative quantification of liver proteins that are regulated by MBH insulin as m
(I and J) Circulating levels of short-chain acyl-CoAs (I) and acylcarnitines (J) th
spectrometry (GC-MS; nR 4 per group). *p < 0.05 compared to control group. V
Cell Mbrain insulin signaling controls BCAA catabolism via regulation
of hepatic BCKDH activity.
High-Fat Feeding Impairs the Ability of Brain Insulin
to Lower Plasma BCAA Levels in Rats
High-fat (HF) diet is well known to impair both peripheral and
central insulin signaling, resulting in an insulin-resistantblot (nR 6 per group).
KDH activity (nR 6 per group).
ing 1-14C KIV (nR 4 per group).
easured by global iTRAQ-based quantitative proteomics (nR 4 per group).
at can be derived from BCAAs as measured by gas chromatography-mass
alues are mean ± SEM.
etabolism 20, 898–909, November 4, 2014 ª2014 Elsevier Inc. 903
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Kor, 1992; Savage et al., 2007). We recently demonstrated that
short-term voluntary overfeeding impairs hypothalamic insulin
action in rats, defined as the ability of MBH insulin to suppress
hepatic glucose production and adipose tissue lipolysis (Scherer
et al., 2012). To test whether overfeeding-induced insulin resis-
tance (a model for common forms of insulin resistance in
humans) impairs the ability of MBH insulin to regulate BCAA
metabolism, we fed rats a palatable 10% lard diet for 3 days, af-
ter which we performed clamp studies as described above,
combining MBH insulin infusions with basal, euglycemic clamps
(protocol in Figure 4A). Circulating BCAA levels did not differ be-
tween HF-fed and normal chow-fed rats at baseline, likely due to
the fact that insulin levels were higher after 3 days of overfeeding.
While MBH insulin was able to effectively suppress circulating
BCAA levels in rats fed regular chow diet (34%; p = 0.06),
this suppression was attenuated by more than 50% (15%; Fig-
ure 4B) in rats on the HF diet, suggesting that excessive nutrient
intake is sufficient to impair central insulin control of BCAA
metabolism.
Hepatic BCKDH Expression Is Reduced in Human
Obesity and Diabetes
Emerging data suggest that human obesity and/or diabetes are
also associated with central insulin resistance (Hallschmid et al.,
2008; Tschritter et al., 2006). If human obesity indeed is associ-
ated with impaired hypothalamic insulin action, then the predic-
tion would be that hepatic BCAA catabolism and BCKDH protein
is reduced, which could account for the increased plasma BCAA
levels. To test this, we measured BCKDH protein in liver and
circulating BCAA levels from obese or obese and diabetic hu-
mans, hypothesizing that hepatic BCKDH expression would be
reduced, while plasma BCAAs would be increased. Obese and
obese-diabetic men showed decreased BCKDH protein expres-
sion in the liver compared to the nonobese control group (Fig-
ure 4G), while in females there was no difference, suggestive
of a sexual dimorphism in the regulation of BCAA metabolism
(Figure 4H).
High-Fat Feeding in Nonhuman Primates Increases
Circulating BCAAs and Lowers the Expression of
Hepatic BCKDH
We next studied male nonhuman primates that had been fed a
HF diet to test if HF diet-induced obesity increases plasma
BCAA levels and reduces hepatic BCKDH expression. After
15 months of HF diet feeding, obese male macaques exhibited
lower hepatic BCKDH protein expression without changes in
its phosphorylation state, indicative of reduced BCKDH activity
(Figures 4C and 4D). Further, hepatic BCKDH protein expression
was negatively and significantly associated with both body
weight and adiposity in macaques (Figures 4E and 4F). Plasma
valine levels strongly correlated with the HOMA index, but not
with trunk fat or hepatic BCKDH protein expression in the male
macaques (Figure S4). In men, BMI correlated with circulating
valine levels (r = 0.53, p = 0.048; Figure 4I) and inversely corre-
lated with hepatic BCKDH protein level (r = 0.79, p = 0.03; Fig-
ure 4J), while HOMA index did not correlate with plasma valine or
hepatic BCKDH protein level (Figure S4). These results indicate
that obesity and/or diabetes is associatedwith increased plasma904 Cell Metabolism 20, 898–909, November 4, 2014 ª2014 ElsevierBCAA levels and linked to lower hepatic BCAA metabolism, and
that these effects are sex-specific.
Role of Neuronal Insulin Signaling in Regulating BCAAs
Is Preserved in C. elegans
C. elegans is a commonly used model organism due to its
genetic tractability.C. elegans expresses the insulin receptor ho-
molog (Daf-2) mainly in neurons (Kenyon et al., 1993) and there-
fore lends itself as amodel of metabolic control through neuronal
insulin signaling. Hence, we tested if BCAA levels are regulated
through neuronal insulin signaling in this phylogenetically distant
organism. Control and Daf-2-deficient worms were fasted for
2 hr, after which the worms were homogenized and BCAA levels
of whole-body lysates were analyzed. BCAA levels were
increased in the Daf-2-deficient worms that lack insulin signaling
(Figure 4K), indicating that the role of brain insulin signaling is
conserved from C. elegans to mammals.
DISCUSSION
Here we demonstrate that insulin action is a critical regulator of
plasma BCAA levels by inducing hepatic BCKDH protein and ac-
tivity. Surprisingly, hyperglycemia per se did not alter BCAA
levels in vivo, indicating that insulin resistance, but not hypergly-
cemia, is a major cause of the increase in circulating BCAAs in
obesity and diabetes. Previous studies have indicated that infu-
sion of glucose lowers plasma BCAAs in men and women (Felig
et al., 1969). Our study demonstrates that this is due to glucose-
induced insulin secretion and not due to a direct effect of glucose
on BCAA metabolism per se. The ability of insulin to induce he-
patic BCKDH activity and lower plasma BCAA levels depends
on brain insulin signaling, specifically hypothalamic insulin
signaling. We conclude this from a series of studies that utilize
complementary approaches, where we manipulated insulin
signaling through either pharmacological and/or genetic loss-
of-function approaches. Further, HF feeding impairs the ability
of brain insulin to induce BCAA catabolism, suggesting that hy-
pothalamic insulin resistance in part underlies the rise of BCAA
plasma concentrations in obesity and diabetes. Since human
obesity may be associated with brain insulin resistance (Tschrit-
ter et al., 2006), we speculated that obese humans and HF-
fed nonhuman primates would exhibit reduced expression of
hepatic BCAA catabolic enzymes. We find that hepatic BCKDH
protein is reduced in obese and diabetic humans as well as
HF-fed macaques, consistent with the concept of impaired brain
insulin action in human obesity and diabetes.
The induction of hyperglycemia during basal insulinemia did
not alter BCAA catabolism, indicating that hyperglycemia per
se is not sufficient to increase BCAA levels and decrease
BCAA catabolism, while circulating BCAA levels were dose-
dependently lowered by insulin during maintained euglycemia.
Although it is possible that the combined effect of hyperglycemia
and hyperinsulinemia could reduce BCAA catabolism, the
glucose infusion rate that would be needed tomaintain hypergly-
cemia during hyperinsulinemia would be extremely high and
likely unphysiological in an insulin-sensitive animal. Nonetheless,
we believe that our studies effectively dissociated the effects of
hyperglycemia and hyperinsulinemia on BCAA catabolism.While
insulin dose-dependently lowered plasma BCAA levels, hepaticInc.
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Figure 4. Acute HF Overfeeding Leads to Impaired Suppression of Circulating BCAAs by MBH Insulin, and Obesity and Diabetes Are Asso-
ciated with Decreased BCKDH Protein in Liver
(A) Schematic representation of euglycemic clamp protocol paired with MBH insulin infusion in SD male rats following 3 days of either regular chow or HF (10%
lard) feeding.
(B) Plasma BCAA levels in chow versus HF-fed groups that were infused with either aCSF or insulin in the MBH (nR 5 per group).
(C) Hepatic BCKDH and phosphorylation state of BCKDH in male macaque monkeys after 1.5 years of HF diet (nR 3 per group).
(D) Ratio of pBCKDH to total BCKDH protein expression as an index of BCKDH activity in liver (nR 3 per group).
(E) Correlation between body weight and hepatic BCKDH protein expression in male macaque monkeys (n = 10).
(F) Correlation between adiposity (%) and hepatic BCKDH protein expression in male macaque monkeys (n = 11).
(G and H) Hepatic BCKDH (G) and phosphorylated state of BCKDH (H) in nonobese, obese, or obese and diabetic males or females (n = 4 per group).
(I and J) Correlation between BMI and plasma valine level (I) or hepatic BCKDH protein of male subjects (nR 7) (J).
(K) BCAA levels in C. elegans deficient of insulin receptors (Daf-2; n R 3 per group). *p < 0.05 compared to control group. Groups with different letters are
significantly different from each other. Values are mean ± SEM.
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mia but was not further increased by marked hyperinsulinemia.
The reason for this discrepancy is not clear, but supraphysiolog-
ical hyperinsulinemia may further decrease BCAA levels,Cell Mpossibly due to other mechanisms such as increased cellular
BCAA uptake via an induction or activation of aromatic amino
acid transporters and/or greater BCAA utilization by increased
protein synthesis. An induction of aromatic amino acidetabolism 20, 898–909, November 4, 2014 ª2014 Elsevier Inc. 905
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matic amino acids.
We used genetic mouse models that lack insulin receptors in
either the brain only, the periphery only, or the whole body
including the CNS in addition to the clamp studies in rats where
we infused insulin centrally. These complementary studies sup-
port the concept that circulating BCAAs and hepatic BCAA
metabolism is regulated by brain insulin. Importantly, the degree
of hyperglycemia and hyperinsulinemia in the two inducible insu-
lin receptor knockout models were comparable at the time these
animals were studied. We observed some minor differences in
body composition in the genetic knockout models used herein,
which could have confounded some of our results. However, he-
patic BCKDH protein expression was lower in the IR DWB mice
despite lower adiposity, which would be predicted to increase
BCKDH expression and activity. Thus, the moderate differences
in body composition would be predicted to cause alterations
in BCKDH expression opposite to what has been observed
here and therefore are unlikely to reduce the validity of our
conclusions.
Both BCKDH protein and activity levels did not seem to be
regulated by insulin in perigonadal WAT as opposed to liver.
The average mass of liver is 12 g, and that of WAT is 3 g in 12-
week-old SD rats; therefore, the total BCKDH activity in liver
induced by insulin would be estimated to be roughly over 500-
fold higher than that in WAT, suggesting that WAT BCKDH activ-
ity is significantly less than that of liver in an insulin-sensitive rat.
This conclusion rests on the assumption that the BCKDH activity
of perigonadal WAT reflects that of other fat depots, which we
did not assess in this study. Furthermore, animals markedly in-
crease their fat mass as they become obese and/or diabetic,
which may alter the relative contribution of hepatic versus adi-
pose BCKDH activity.
Circulating BCAAs are sensed by the hypothalamus, which in
turn can alter nutrient metabolism. The effects of central BCAAs
such as leucine on hypothalamic control of systemic metabolism
are somewhat controversial. Cota et al. (2006) and others (Blouet
et al., 2009; Morrison et al., 2007) have shown that central
administration of leucine increases activation of mammalian
target of rapamycin (mTOR) and S6K and reduces food intake,
suggesting that hypothalamic BCAAs are important in limiting
food intake. However, it is likely that the ability of BCAAs to exert
this anorexigenic effect is lost in the obese and/or diabetic state.
Further, BCAAs may trigger hypothalamic insulin resistance via
hypothalamic mTOR overactivation to induce hepatic insulin
resistance that would, in turn, impair systemic metabolism. In
support of this, Ono et al. (2008) found that constitutive S6K acti-
vation in the hypothalamus can be a cause of hypothalamic insu-
lin resistance. Based on our and others’ findings, we speculate
that the increased circulating BCAA levels experienced by obese
and/or diabetic individuals may lead to hyperactivation of the
mTORpathwaywithin theMBH that impairs hypothalamic insulin
action, worsening systemic insulin resistance and thus starting a
vicious cycle. Conversely, the reduction of circulating BCAAs
seen after bariatric surgery of obese individuals could be due
to restored hypothalamic insulin signaling, a hypothesis we are
currently examining. Whether a reduction of circulating BCAAs
through the induction of BCAA catabolism is sufficient to
improve glucose homeostasis remains to be tested.906 Cell Metabolism 20, 898–909, November 4, 2014 ª2014 ElsevierWe observed sexual dimorphism in the regulation of BCKDH
levels in nonhuman primates. This finding mirrors that of a rodent
studywhere sexual dimorphism in the diurnal variation in BCKDH
activity in liver has been demonstrated (Kobayashi et al., 1997).
Further, differences in the predictive values of BCAAs for insulin
resistance were also reported to be sexually dimorphic in young
human adults (Wu¨rtz et al., 2013). The reason for the lack of as-
sociation between obesity and diabetes in females and hepatic
BCKDH protein expression is not clear, but the presence of
sex difference may suggest that the male macaques are more
sensitive to HF diet-induced central insulin resistance, while
females are more tolerant to HF feeding and are protected
from central insulin resistance. Human studies demonstrate
that men are diagnosed with diabetes at a lower BMI compared
to women across the age spectrum in a European cohort, sug-
gesting that men are more susceptible to developing diabetes
than women (Logue et al., 2011). The lack of HF diet-induced
changes in BKCDH expression in liver of females may be a
reflection or even a mechanism for their improved metabolic
state during chronic HF feeding.
Collectively, these results suggest that brain insulin plays a crit-
ical role in the regulation of systemic BCAA metabolism, a meta-
bolic pathway that is evolutionarily conserved from worm to
mammals. Increased plasma BCAAs in obese and/or diabetic in-
dividualsmaybedue to impairedCNS insulin action. Thus,plasma
BCAAs may represent a marker of hypothalamic insulin action.
EXPERIMENTAL PROCEDURES
Animals
Male Sprague-Dawley (SD) rats (8–10 weeks old; Charles River Laboratories)
were provided with either standard laboratory chow (Rodent Diet 5001,
LabDiet) or a high-fat diet (5704C-K, purified modified rodent 10% lard, Test-
Diet). Animals were housed in separate cages at a constant ambient temper-
ature of 21C –23C with a 12 hr light-dark cycle (lights on at 0700 hr, off at
1900 hr). Before pancreatic clamp studies, rats underwent stereotaxic implan-
tation of indwelling cannulae targeting the MBH as previously described
(Scherer et al., 2011). The coordinates for the MBH cannulae implantations
were 3.3 mm posterior from bregma, 0.4 mm bilateral from midline, and
9.6 mm below the surface of the skull. After 7 days of recovery, rats were im-
planted with carotid and jugular catheters. Rats were allowed to recover for an
additional 4–6 days and had to return to within 10% of their presurgical body
weight. Insulin (Humulin R, Lilly) at a concentration of 1 mU/ml was infused at a
rate of 0.003 ml/min for 6 hr bilaterally into theMBH according to the clamp pro-
tocol, resulting in the delivery of 2.2 mU to the MBH. These coordinates had
been previously validated where the spread of the infusate was assessed by
infusion of radioactive tracers followed by sampling of several hypothalamic
nuclei by micropunches such as the VMH, arcuate, and PVN. It was found
that the infusate spread was contained to the arcuate and did not extend to
the other nuclei (Lam et al., 2005). We routinely infused food dye immediately
before removing the brain to confirm correct anatomical placement of the
cannulae.
SD rats (3–4 months old) were fed a high-fat diet for 3 days before the MBH
infusion experiment. For the HF feeding study, rats were fed either standard
chow, which provided 59% calories from carbohydrates, 20% from protein,
and 21% from fat, or the same diet supplemented with 10% lard, which pro-
vided 45% of calories from carbohydrates, 22% from protein, and 33% from
fat. This led to an average increase of daily caloric intake from 61 to 83 kcal.
Neuronal-specific insulin receptor knockout (NIRKO) mice were generated
by crossing mice homozygous for the floxed insulin receptor allele with trans-
genic mice that express Cre recombinase under the control of nestin promoter
(Bru¨ning et al., 2000). IRDWBmice were purchased from Taconic, and knockout
of insulin receptors in thewhole body, including the brain, was induced by add-
ing 2.5 mg/kg doxycycline in 5% glucose drinking water throughout the study.Inc.
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generated by crossing IRflox/flox mice with RosaCre mice expressing Cre re-
combinase fused to the mutated ligand domain of estrogen receptor (ER)
(Koch et al., 2008), and recombination was induced by an intraperitoneal
(i.p.) injection of tamoxifen (1.5 mg/day) for 5 consecutive days. Blood glucose
was monitored daily. The mice were on a 12 hr light-dark cycle and fed a stan-
dard rodent diet (Mouse Diet 9F, PMI Nutrition International) unless otherwise
noted.
All protocols involved in the animal studies were approved by the Institu-
tional Animal Care and Use Committee at the Icahn School of Medicine at
Mount Sinai in accordance with guidelines established by the National Insti-
tutes of Health. Protocols involved in the monkey study were approved by
the Institutional Animal Care and Use Committee at Mount Sinai School of
Medicine and at the Oregon National Primate Research Center at Oregon
Health & Science University in accordance with guidelines established by
the National Institutes of Health. The human study was approved by the Med-
ical Ethical Board of the Maastricht University Medical Centre in line with the
revised version of the Declaration of Helsinki (October 2008, Seoul), and
informed consent in writing was obtained from each subject.
Worm Strains
The following strainswere provided by Caenorhabditis Genetics Center (CGC):
wild-type (N2) and daf-2 (e1370). Caenorhabditis elegans wild-type worms
were maintained on nematode growth media (NGM) at 20C, while daf-2 mu-
tants were maintained at 15C. Worms were fed Escherichia coli OP50.
Worm Extraction
Worms were maintained at 20C and were washed off the plates with deion-
ized water 3 days after axenization. Worms were allowed to sink to the bottom
of microcentrifuge tubes and washed three times with water, after which
worms were just maintained for another 2 hr in water to allow transitioning
into the fasting state, at which point they were pelleted and sonicated in a lysis
buffer made of 20 mM MOPS, 2 mM EGTA, 5 mM EDTA, 30 mM sodium
fluoride, 40 mM b-glycerophosphate, 10 mM sodium pyrophosphate, 2 mM
sodium orthovanadate, 0.5% NP-40, and complete protease inhibitor cocktail
(Roche) and centrifuged at 13,0003 g for 15 min at 4C. Protein concentration
in the supernatant was measured with the BCA protein quantification kit
(Thermo Scientific). The supernatant was then stored in a 80C freezer and
used for further analysis.
Mouse Fasting and Refeeding Study
NIRKO and littermate control mice (3 months old) were deprived of food for
24 hr starting at 5 p.m. before the experiment, so the refeeding period coin-
cided with the onset of the feeding cycle (protocol depicted in Figure 3A). An
initial blood sample was taken by tail bleeding at t = 0 min, after which mice
were given access to regular chow for 2 hr. The final blood sample (t =
120 min) was obtained via tail bleed. Animals were anesthetized via isoflurane,
after which they were decapitated, and organs including liver were harvested
and clamp frozen for western blot analysis.
Other Analytic Procedures
Blood glucose levels during the clamp were measured by hand-held glucom-
eter (Onetouch Ultra Blood Glucose Monitor, LifeScan). Glucose flux and Ra
glycerol were analyzed as described elsewhere (Obici et al., 2002; Scherer
et al., 2011). Plasma free glycerol and triglycerides were measured with a
colorimetric assay from Sigma-Aldrich and plasma NEFA with a kit from
Wako Chemicals. Plasma insulin was analyzed by species-specific ELISA kit
from Mercodia.
Western Blots
At the end of clamp study, animals were anesthetized with isoflurane and
sacrificed by decapitation, and liver, muscle, kidney, and adipose tissue
were harvested and freeze clamped in liquid nitrogen. The frozen samples
were kept at 80C until they were processed for western blots as previously
described (Scherer et al., 2011). Briefly, 100 mg of tissue was homogenized
in lysis buffer and sonicated for 15 s. The homogenates were centrifuged at
13,000 rpm at 4C for 20 min, and the supernatants were collected. Protein
amount was quantified by BCA Protein Assay kit (Pierce), and 20 mg of proteinCell Mwas loaded in 4%–12% NuPAGE gels (Invitrogen). Primary antibodies against
branched-chain a-ketoacid dehydrogenase (BCKDH) total 32–50, 371–90,
and phosphorylated form of BCKDH were generated and characterized
as previously described (Lynch et al., 2003; Sweatt et al., 2004). Anti-
bodies against branched-chain aminotransferase (BCATm) were purchased
from Abcam. Blots were scanned with the LI-COR Odyssey (LI-COR) and
quantified with Odyssey 3.0 software on the basis of direct fluorescence
measurement.
BCAA Assay
A spectrophotometric assay was employed to measure total BCAAs (leucine,
isoleucine, and valine) from plasma samples as described previously (Beckett,
2000).
Serum Acylcarnitines and Amino Acids
A panel of plasma acylcarnitines and amino acids were analyzed byMS/MS as
described previously (Ferrara et al., 2008).
Circulating Free Fatty Acids and Organic Acids in Liver
Capillary gas chromatography-mass spectrometry (GS-MS) with TRACE DSQ
instrument (Thermo Electron Corporation) was used to analyze the derivatized
fatty acids in the plasma and organic acids in the liver samples as described
previously (Newgard et al., 2009).
Statistics
Plasma glucose levels during the clamp were analyzed by two-way repeated-
measures ANOVA, with treatment as a between-subject factor and time as a
within-subject factor, followed by Bonferroni post hoc multiple comparisons.
Proteomics data, body weight, cumulative food intake, and plasma insulin
were analyzed by Student’s t test to compare the mean difference between
vehicle versus MBH insulin treatment. Clamp data, plasma BCAA levels,
acylcarnitines, amino acids, derivatized CoAs, and western blot protein
expression data were analyzed by one-way ANOVA followed by Bonferroni
post hoc test. Correlation analyses were conducted to determine the associ-
ation between insulin sensitivity, BMI, hepatic BCKDH protein, and plasma
valine. All data are expressed as mean ± SEM. Significant difference was set
at p < 0.05.
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